Boron Neutron Capture Therapy for Recurrent Glioblastoma Multiforme: Imaging Evaluation of a Case With Long-Term Local Control and Survival

Glioblastoma (GBM) is difficult to cure with conventional multimodal treatment and has an extremely poor prognosis. Boron neutron capture therapy (BNCT) is a new particle therapy for malignant tumors in the brain and head and neck region. This radiotherapy utilizes a nuclear reaction between neutrons and a nonradioactive isotope, boron-10. In this method, a boron compound is administered transvenously into the body. The boron compound has the property of being selectively taken up only by the cells of malignant tumors, and the subsequent irradiation with neutrons can destroy malignant tumor cells without damaging normal cells. Since the irradiation dose to normal tissues is reduced in BNCT, it may be possible to re-irradiate malignant tumors that recur after radiotherapy. Clinical trials have reported prolonged survival and safety of BNCT in a small number of patients with refractory malignancies, including GBM, but these reports do not address quality of life or activities of daily living (ADL) after treatment, and there is no information on the assessment of local control by imaging. Here, we report a case of GBM that recurred after surgery, 60 Gy of conventional radiotherapy and standard treatment with temozolomide. The patient achieved long-term local control and survival over five years after BNCT and was able to maintain ADL at home without any specialist care. We describe the case with evaluation using longitudinal magnetic resonance imaging (MRI).

[1]  H. Sakurai,et al.  Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis , 2021, BMC Neurology.

[2]  D. Trifiletti,et al.  Boron Neutron Capture Therapy: A Review of Clinical Applications , 2021, Frontiers in Oncology.

[3]  Joe Y. Chang,et al.  Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues , 2019, Molecular Cancer.

[4]  M. Irie Brain Tumor Registry of Japan (2005–2008) , 2017, Neurologia medico-chirurgica.

[5]  Y. Narita,et al.  Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan , 2015, Neurologia medico-chirurgica.

[6]  M. Galea,et al.  Effectiveness of integrated multidisciplinary rehabilitation in primary brain cancer survivors in an Australian community cohort: a controlled clinical trial. , 2014, Journal of Rehabilitation Medicine.

[7]  A. Matsumura,et al.  Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy. , 2011, The British journal of radiology.

[8]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[10]  A. Matsumura,et al.  Boron neutron capture therapy for newly diagnosed glioblastoma. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  A. Munshi,et al.  Factors influencing activities of daily living using FIM–FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study , 2009, Journal of Neuro-Oncology.

[12]  L. Pellettieri,et al.  An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme , 2008, Acta neurologica Scandinavica.

[13]  J. Debus,et al.  Stereotactic radiosurgery (SRS) , 2005, Cancer.

[14]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[15]  K. Hoang-Xuan,et al.  Treatment of Malignant Gliomas in the Elderly , 1999, Journal of Neuro-Oncology.

[16]  P. Warnke,et al.  Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. , 1993, Journal of neurosurgery.

[17]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[18]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[19]  OUP accepted manuscript , 2022, Japanese Journal Of Clinical Oncology.

[20]  D. Rades,et al.  Palliative Radiotherapy of Primary Glioblastoma , 2021, In Vivo.

[21]  M. Weller,et al.  Chapter 23 - Glioblastoma , 2016 .

[22]  T. Kageji,et al.  Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment. , 2014, The journal of medical investigation : JMI.

[23]  S. Miyatake,et al.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas , 2008, Journal of Neuro-Oncology.

[24]  D. Harvey,et al.  Rehabilitation in primary and metastatic brain tumours Impact of functional outcomes on survival , 2008 .

[25]  J. Jääskeläinen,et al.  Debulking or biopsy of malignant glioma in elderly people – a randomised study , 2003, Acta Neurochirurgica.